Alumis (ALMS) FCF Margin (2025)
Alumis (ALMS) reported FCF Margin of 3727.68% for Q4 2025, up 30.57% quarter-over-quarter from 5368.64% in Q3 2025.
Alumis (ALMS) FCF Margin (2025) Analysis & Trends
Alumis (ALMS) has 1 years of FCF Margin data on file, last reported at 3727.68% in Q4 2025.
- FCF Margin for Q4 2025 came in at 3727.68%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 1539.19% (changed N/A YoY), and the FY2025 annual result was 1539.19%, changed N/A from the prior year.
- FCF Margin advanced to 3727.68% in Q4 2025 per ALMS's latest filing, from 5368.64% in the prior quarter.
- Over five years, FCF Margin peaked at 462.32% in Q1 2025 and troughed at 5368.64% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | -3,727.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3,727.68% |
| Sep 30, 2025 | -5,368.64% |
| Jun 30, 2025 | -4,012.04% |
| Mar 31, 2025 | -462.32% |